broad_id
string | depmap_id
string | ccle_name
string | screen_id
string | upper_limit
int64 | lower_limit
float64 | slope
float64 | r2
float64 | auc
float64 | ec50
float64 | ic50
float64 | name
string | moa
string | target
string | disease.area
string | indication
string | smiles
string | phase
string | passed_str_profiling
bool | row_name
string |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
BRD-K57080016-001-15-9 | ACH-001016 | BECKER_CENTRAL_NERVOUS_SYSTEM | MTS010 | 1 | 0.883334 | -0.802778 | 0.120983 | 0.982071 | 0.001735 | null | selumetinib | MEK inhibitor | MAP2K1 | null | null | Cn1cnc2c(F)c(Nc3ccc(Br)cc3Cl)c(cc12)C(=O)NOCCO, Cn1cnc2c(F)c(Nc3ccc(Br)cc3Cl)c(cc12)C(=O)NOCCO | Phase 3 | true | ACH-001016 |
BRD-K57169635-001-04-5 | ACH-001016 | BECKER_CENTRAL_NERVOUS_SYSTEM | MTS010 | 1 | 0.172285 | 2.668046 | 0.753182 | 0.929869 | 4.593455 | 5.381538 | dacomitinib | EGFR inhibitor | EGFR, ERBB2, ERBB4 | null | null | COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)\C=C\CN1CCCCC1 | Phase 3 | true | ACH-001016 |
BRD-K58435339-001-03-0 | ACH-001016 | BECKER_CENTRAL_NERVOUS_SYSTEM | MTS010 | 1 | 0.39936 | 3.451752 | 0.617361 | 0.660881 | 0.041727 | 0.066391 | AT13387 | HSP antagonist | HSP90AA1 | null | null | CC(C)c1cc(C(=O)N2Cc3ccc(CN4CCN(C)CC4)cc3C2)c(O)cc1O, CC(C)c1cc(C(=O)N2Cc3ccc(CN4CCN(C)CC4)cc3C2)c(O)cc1O | Phase 2 | true | ACH-001016 |
BRD-K58529924-001-01-5 | ACH-001016 | BECKER_CENTRAL_NERVOUS_SYSTEM | MTS010 | 1 | 1.033635 | -0.06112 | -0.03181 | 1 | 98,727.48622 | null | ONC201 | AKT inhibitor, MAP kinase inhibitor | TNFSF10 | null | null | Cc1ccccc1CN1C2=NCCN2C2=C(CN(Cc3ccccc3)CC2)C1=O | Phase 2 | true | ACH-001016 |
BRD-K58550667-001-08-7 | ACH-001016 | BECKER_CENTRAL_NERVOUS_SYSTEM | MTS010 | 1 | 0.237018 | 7.482918 | 0.855913 | 0.810508 | 0.056113 | 0.061145 | FK-866 | niacinamide phosphoribosyltransferase inhibitor | NAMPT | null | null | O=C(NCCCCC1CCN(CC1)C(=O)c1ccccc1)\C=C\c1cccnc1 | Phase 2 | true | ACH-001016 |
BRD-K59317601-001-05-5 | ACH-001016 | BECKER_CENTRAL_NERVOUS_SYSTEM | MTS010 | 1 | 0.312911 | 1.088775 | 0.937832 | 0.70513 | 0.156525 | 0.386097 | MLN0128 | mTOR inhibitor | MTOR, PIK3CA, PIK3CD, PIK3CG | null | null | CC(C)n1nc(-c2ccc3oc(N)nc3c2)c2c(N)ncnc12 | Phase 2 | true | ACH-001016 |
BRD-K59369769-001-22-9 | ACH-001016 | BECKER_CENTRAL_NERVOUS_SYSTEM | MTS010 | 1 | 1.035565 | -0.161107 | -0.024683 | 1 | 4.696096 | null | tozasertib | Aurora kinase inhibitor, Bcr-Abl kinase inhibitor, FLT3 inhibitor, JAK inhibitor | AURKA, AURKB, AURKC, LCK | null | null | CN1CCN(CC1)c1cc(Nc2cc(C)[nH]n2)nc(Sc2ccc(NC(=O)C3CC3)cc2)n1, CN1CCN(CC1)c1cc(Nc2cc(C)[nH]n2)nc(Sc2ccc(NC(=O)C3CC3)cc2)n1 | Phase 2 | true | ACH-001016 |
BRD-K60866521-001-07-1 | ACH-001016 | BECKER_CENTRAL_NERVOUS_SYSTEM | MTS010 | 1 | 1.028186 | 0.35363 | -0.054655 | 1 | 0.030655 | null | idelalisib | PI3K inhibitor | PIK3CA, PIK3CB, PIK3CD, PIK3CG | hematologic malignancy | chronic lymphocytic leukemia (CLL) | CC[C@H](Nc1ncnc2[nH]cnc12)c1nc2cccc(F)c2c(=O)n1-c1ccccc1 | Launched | true | ACH-001016 |
BRD-K60997853-001-02-3 | ACH-001016 | BECKER_CENTRAL_NERVOUS_SYSTEM | MTS010 | 1 | -0.124384 | 4.59587 | 0.734512 | 0.963187 | 7.708578 | 7.344842 | PHA-848125 | CDK inhibitor, growth factor receptor inhibitor | CDK2, CDK4, CDK7, NTRK1 | null | null | CNC(=O)c1nn(C)c-2c1C(C)(C)Cc1cnc(Nc3ccc(cc3)N3CCN(C)CC3)nc-21 | Phase 2 | true | ACH-001016 |
BRD-K61192372-001-08-9 | ACH-001016 | BECKER_CENTRAL_NERVOUS_SYSTEM | MTS010 | 1 | 0.791238 | -0.285912 | 0.034794 | 0.907663 | 0.030626 | null | capecitabine | DNA synthesis inhibitor, thymidylate synthase inhibitor | TYMS | oncology | breast cancer, colorectal cancer | CCCCCOC(=O)Nc1nc(=O)n(cc1F)[C@@H]1O[C@H](C)[C@@H](O)[C@H]1O, CCCCCOC(=O)Nc1nc(=O)n(cc1F)[C@@H]1O[C@H](C)[C@@H](O)[C@H]1O, CCCCCOC(=O)Nc1nc(=O)n(cc1F)[C@@H]1O[C@H](C)[C@@H](O)[C@H]1O, CCCCCOC(=O)Nc1nc(=O)n(cc1F)[C@@H]1O[C@H](C)[C@@H](O)[C@H]1O | Launched | true | ACH-001016 |
BRD-K62008436-001-23-9 | ACH-001016 | BECKER_CENTRAL_NERVOUS_SYSTEM | MTS010 | 1 | 0.098949 | 7.368476 | 0.905367 | 0.486037 | 0.002464 | 0.002539 | paclitaxel | tubulin polymerization inhibitor | BCL2, MAP2, MAP4, MAPT, NR1I2, TLR4, TUBB, TUBB1 | oncology | ovarian cancer, breast cancer, non-small cell lung cancer (NSCLC) | CC(=O)O[C@@H]1C2=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)c3ccccc3)[C@@H]3[C@@]4(CO[C@@H]4C[C@H](O)[C@@]3(C)C1=O)OC(C)=O)C2(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)c1ccccc1)c1ccccc1, CC(=O)O[C@@H]1C2=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)c3ccccc3)[C@@H]3[C@@]4(CO[C@@H]4C[C@H](O)[C@@]3(C)C1=O)OC(C)=O)C2(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)c1ccccc1)c1ccccc1, CC(=O)O[C@@H]1C2=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)c3ccccc3)[C@@H]3[C@@]4(CO[C@@H]4C[C@H](O)[C@@]3(C)C1=O)OC(C)=O)C2(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)c1ccccc1)c1ccccc1, CC(=O)O[C@@H]1C2=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)c3ccccc3)[C@@H]3[C@@]4(CO[C@@H]4C[C@H](O)[C@@]3(C)C1=O)OC(C)=O)C2(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)c1ccccc1)c1ccccc1, CC(=O)O[C@@H]1C2=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)c3ccccc3)[C@@H]3[C@@]4(CO[C@@H]4C[C@H](O)[C@@]3(C)C1=O)OC(C)=O)C2(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)c1ccccc1)c1ccccc1 | Launched | true | ACH-001016 |
BRD-K62196610-001-01-6 | ACH-001016 | BECKER_CENTRAL_NERVOUS_SYSTEM | MTS010 | 1 | 0.925891 | 0.671641 | 0.084292 | 0.956583 | 0.031633 | null | AVN-944 | inosine monophosphate dehydrogenase inhibitor | IMPDH1, IMPDH2 | null | null | CC[C@H](CC#N)OC(=O)N[C@@H](C)c1cccc(NC(=O)Nc2ccc(-c3cnco3)c(OC)c2)c1 | Phase 2 | true | ACH-001016 |
BRD-K62200014-003-10-5 | ACH-001016 | BECKER_CENTRAL_NERVOUS_SYSTEM | MTS010 | 1 | 0.342445 | -1.005892 | 0.199227 | 0.970517 | 0.000336 | null | anagrelide | phosphodiesterase inhibitor | PDE3A | hematology, hematologic malignancy | thrombocythemia, myeloproliferative neoplasms | Clc1ccc2N=C3NC(=O)CN3Cc2c1Cl, Clc1ccc2N=C3NC(=O)CN3Cc2c1Cl, Clc1ccc2N=C3NC(=O)CN3Cc2c1Cl | Launched | true | ACH-001016 |
BRD-K62391742-001-09-7 | ACH-001016 | BECKER_CENTRAL_NERVOUS_SYSTEM | MTS010 | 1 | 1.486835 | 0.884811 | 0.114782 | 1 | 14.063833 | null | venetoclax | BCL inhibitor | BCL2 | hematologic malignancy | chronic lymphocytic leukemia (CLL) | CC1(C)CCC(CN2CCN(CC2)c2ccc(C(=O)NS(=O)(=O)c3ccc(NCC4CCOCC4)c(c3)[N+]([O-])=O)c(Oc3cnc4[nH]ccc4c3)c2)=C(C1)c1ccc(Cl)cc1, CC1(C)CCC(CN2CCN(CC2)c2ccc(C(=O)NS(=O)(=O)c3ccc(NCC4CCOCC4)c(c3)[N+]([O-])=O)c(Oc3cnc4[nH]ccc4c3)c2)=C(C1)c1ccc(Cl)cc1, CC1(C)CCC(CN2CCN(CC2)c2ccc(C(=O)NS(=O)(=O)c3ccc(NCC4CCOCC4)c(c3)[N+]([O-])=O)c(Oc3cnc4[nH]ccc4c3)c2)=C(C1)c1ccc(Cl)cc1 | Launched | true | ACH-001016 |
BRD-K62627508-001-01-5 | ACH-001016 | BECKER_CENTRAL_NERVOUS_SYSTEM | MTS010 | 1 | 0.940172 | -1.885674 | -0.188724 | 0.969875 | 0.080817 | null | idasanutlin | MDM inhibitor | MDM2, TP53 | null | null | COc1cc(ccc1NC(=O)[C@@H]1N[C@@H](CC(C)(C)C)[C@@](C#N)([C@H]1c1cccc(Cl)c1F)c1ccc(Cl)cc1F)C(O)=O | Phase 3 | true | ACH-001016 |
BRD-K63504947-001-14-7 | ACH-001016 | BECKER_CENTRAL_NERVOUS_SYSTEM | MTS010 | 1 | 1.112926 | -0.470772 | -0.07663 | 1 | 0.897506 | null | semaxanib | VEGFR inhibitor | FGFR1, FLT1, KDR, KIT, PDGFRA, PDGFRB, RET | null | null | Cc1cc(C)c(\C=C2/C(=O)Nc3ccccc23)[nH]1, Cc1cc(C)c(\C=C2/C(=O)Nc3ccccc23)[nH]1, Cc1cc(C)c(\C=C2/C(=O)Nc3ccccc23)[nH]1, Cc1cc(C)c(\C=C2/C(=O)Nc3ccccc23)[nH]1 | Phase 3 | true | ACH-001016 |
BRD-K63712959-001-01-8 | ACH-001016 | BECKER_CENTRAL_NERVOUS_SYSTEM | MTS010 | 1 | 1.066397 | 1.383897 | 0.113533 | 1 | 0.139713 | null | temoporfin | radical formation stimulant | null | oncology | head and neck squamous cell carcinoma (HNSCC) | Oc1cccc(c1)-c1c2CCc(n2)c(-c2cccc(O)c2)c2ccc([nH]2)c(-c2cccc(O)c2)c2ccc(n2)c(-c2cccc(O)c2)c2ccc1[nH]2 | Launched | true | ACH-001016 |
BRD-K64052750-001-22-5 | ACH-001016 | BECKER_CENTRAL_NERVOUS_SYSTEM | MTS010 | 1 | 0.805563 | 0.005051 | -0.061879 | 0.902567 | 0.032657 | null | gefitinib | EGFR inhibitor | EGFR | oncology | non-small cell lung cancer (NSCLC) | COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1, COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1, COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1, COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1 | Launched | true | ACH-001016 |
BRD-K64881305-001-03-7 | ACH-001016 | BECKER_CENTRAL_NERVOUS_SYSTEM | MTS010 | 1 | 0.149149 | 2.912282 | 0.962334 | 0.385331 | 0.00902 | 0.010186 | ispinesib | kinesin inhibitor | KIF11 | null | null | CC(C)[C@@H](N(CCCN)C(=O)c1ccc(C)cc1)c1nc2cc(Cl)ccc2c(=O)n1Cc1ccccc1, CC(C)[C@@H](N(CCCN)C(=O)c1ccc(C)cc1)c1nc2cc(Cl)ccc2c(=O)n1Cc1ccccc1, CC(C)[C@@H](N(CCCN)C(=O)c1ccc(C)cc1)c1nc2cc(Cl)ccc2c(=O)n1Cc1ccccc1 | Phase 2 | true | ACH-001016 |
BRD-K66175015-001-12-4 | ACH-001016 | BECKER_CENTRAL_NERVOUS_SYSTEM | MTS010 | 1 | 0.048473 | 3.144246 | 0.819624 | 0.926867 | 4.897551 | 5.05899 | afatinib | EGFR inhibitor | EGFR, ERBB2, ERBB4 | oncology | non-small cell lung cancer (NSCLC) | CN(C)C\C=C\C(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1O[C@H]1CCOC1, CN(C)C\C=C\C(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1O[C@H]1CCOC1, CN(C)C\C=C\C(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1O[C@H]1CCOC1 | Launched | true | ACH-001016 |
BRD-K67844266-003-01-9 | ACH-001016 | BECKER_CENTRAL_NERVOUS_SYSTEM | MTS010 | 1 | 2.349695 | 4.372803 | -0.076629 | 1 | 150.675929 | null | pevonedistat | nedd activating enzyme inhibitor | NAE1, UBA3 | null | null | NS(=O)(=O)OC[C@@H]1C[C@H](C[C@@H]1O)n1ccc2c(N[C@H]3CCc4ccccc34)ncnc12 | Phase 2 | true | ACH-001016 |
BRD-K69001009-001-02-8 | ACH-001016 | BECKER_CENTRAL_NERVOUS_SYSTEM | MTS010 | 1 | 1.018584 | -0.320978 | -0.043297 | 1 | 6.096152 | null | golvatinib | VEGFR inhibitor | KDR, MET | null | null | CN1CCN(CC1)C1CCN(CC1)C(=O)Nc1cc(Oc2ccc(NC(=O)C3(CC3)C(=O)Nc3ccc(F)cc3)c(F)c2)ccn1 | Phase 2 | true | ACH-001016 |
BRD-K69694239-001-02-2 | ACH-001016 | BECKER_CENTRAL_NERVOUS_SYSTEM | MTS010 | 1 | 0.806068 | -3.198106 | -0.087782 | 0.942183 | 0.011011 | null | bardoxolone-methyl | nuclear factor erythroid derived, like (NRF2) activator | PPARG, STAT3 | null | null | COC(=O)[C@]12CCC(C)(C)C[C@H]1[C@H]1C(=O)C=C3[C@@]4(C)C=C(C#N)C(=O)C(C)(C)[C@@H]4CC[C@@]3(C)[C@]1(C)CC2 | Phase 3 | true | ACH-001016 |
BRD-K69776681-001-03-8 | ACH-001016 | BECKER_CENTRAL_NERVOUS_SYSTEM | MTS010 | 1 | 0.340943 | 2.011087 | 0.11414 | 0.519228 | 0.008402 | 0.014849 | volasertib | PLK inhibitor | PLK1 | null | null | CC[C@H]1N(C(C)C)c2nc(Nc3ccc(cc3OC)C(=O)N[C@H]3CC[C@@H](CC3)N3CCN(CC4CC4)CC3)ncc2N(C)C1=O, CC[C@H]1N(C(C)C)c2nc(Nc3ccc(cc3OC)C(=O)N[C@H]3CC[C@@H](CC3)N3CCN(CC4CC4)CC3)ncc2N(C)C1=O | Phase 3 | true | ACH-001016 |
BRD-K70301465-001-05-9 | ACH-001016 | BECKER_CENTRAL_NERVOUS_SYSTEM | MTS010 | 1 | 0.914449 | 2.022068 | 0.098031 | 0.929554 | 0.003332 | null | ibrutinib | Bruton's tyrosine kinase (BTK) inhibitor | BLK, BMX, BTK | hematologic malignancy | chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL), Waldenstrom's macroglobulinemia (WM) | Nc1ncnc2n(nc(-c3ccc(Oc4ccccc4)cc3)c12)[C@@H]1CCCN(C1)C(=O)C=C, Nc1ncnc2n(nc(-c3ccc(Oc4ccccc4)cc3)c12)[C@@H]1CCCN(C1)C(=O)C=C | Launched | true | ACH-001016 |
BRD-K70401845-001-15-7 | ACH-001016 | BECKER_CENTRAL_NERVOUS_SYSTEM | MTS010 | 1 | 0.876139 | 1.643133 | 0.250353 | 0.949858 | 0.19687 | null | erlotinib | EGFR inhibitor | EGFR, NR1I2 | oncology | non-small cell lung cancer (NSCLC), pancreatic cancer | COCCOc1cc2ncnc(Nc3cccc(c3)C#C)c2cc1OCCOC, COCCOc1cc2ncnc(Nc3cccc(c3)C#C)c2cc1OCCOC | Launched | true | ACH-001016 |
BRD-K73838513-003-05-5 | ACH-001016 | BECKER_CENTRAL_NERVOUS_SYSTEM | MTS010 | 1 | 0.682833 | 1.098955 | 0.356148 | 0.974223 | 7.462932 | null | cinacalcet | calcium channel activator | CASR | endocrinology, nephrology, oncology | hyperparathyroidism, chronic kidney disease (CKD), parathyroid carcinoma, hypercalcemia | C[C@@H](NCCCc1cccc(c1)C(F)(F)F)c1cccc2ccccc12 | Launched | true | ACH-001016 |
BRD-K74514084-003-09-2 | ACH-001016 | BECKER_CENTRAL_NERVOUS_SYSTEM | MTS010 | 1 | 0.953839 | -7.427841 | 0.129018 | 0.977626 | 0.067317 | null | pazopanib | KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor | CSF1R, FGF1, FGFR1, FGFR3, FLT1, FLT4, ITK, KDR, KIT, PDGFRA, PDGFRB, SH2B3 | oncology | renal cell carcinoma (RCC), soft tissue sarcoma (STS) | CN(c1ccc2c(C)n(C)nc2c1)c1ccnc(Nc2ccc(C)c(c2)S(N)(=O)=O)n1, CN(c1ccc2c(C)n(C)nc2c1)c1ccnc(Nc2ccc(C)c(c2)S(N)(=O)=O)n1 | Launched | true | ACH-001016 |
BRD-K75009076-001-02-1 | ACH-001016 | BECKER_CENTRAL_NERVOUS_SYSTEM | MTS010 | 1 | -0.021913 | 0.857442 | 0.715308 | 0.767158 | 1.322175 | 1.25766 | SCH-900776 | CHK inhibitor | CDK2, CHEK1 | null | null | Cn1cc(cn1)-c1cnn2c(N)c(Br)c(nc12)[C@@H]1CCCNC1, Cn1cc(cn1)-c1cnn2c(N)c(Br)c(nc12)[C@@H]1CCCNC1 | Phase 2 | true | ACH-001016 |
BRD-K76210423-001-01-6 | ACH-001016 | BECKER_CENTRAL_NERVOUS_SYSTEM | MTS010 | 1 | 0.884999 | -4.612475 | 0.267546 | 0.942111 | 0.080703 | null | resiquimod | toll-like receptor agonist | TLR7, TLR8 | null | null | CCOCc1nc2c(N)nc3ccccc3c2n1CC(C)(C)O, CCOCc1nc2c(N)nc3ccccc3c2n1CC(C)(C)O | Phase 3 | true | ACH-001016 |
BRD-K76239644-001-02-6 | ACH-001016 | BECKER_CENTRAL_NERVOUS_SYSTEM | MTS010 | 1 | 0.773011 | 0.570449 | 0.200709 | 0.900537 | 0.154504 | null | BMS-690514 | EGFR inhibitor, VEGFR inhibitor | EGFR, ERBB2, FLT3, KDR | null | null | COc1cccc(Nc2ncnn3ccc(CN4CC[C@@H](N)[C@H](O)C4)c23)c1, COc1cccc(Nc2ncnn3ccc(CN4CC[C@@H](N)[C@H](O)C4)c23)c1 | Phase 2 | true | ACH-001016 |
BRD-K76674262-001-03-3 | ACH-001016 | BECKER_CENTRAL_NERVOUS_SYSTEM | MTS010 | 1 | 0.142788 | 11.986779 | 0.928495 | 0.728917 | 0.464689 | 0.477908 | homoharringtonine | protein synthesis inhibitor | RPL3 | hematologic malignancy | chronic myeloid leukemia (CML) | COC(=O)C[C@](O)(CCCC(C)(C)O)C(=O)O[C@H]1[C@H]2c3cc4OCOc4cc3CCN3CCC[C@]23C=C1OC | Launched | true | ACH-001016 |
BRD-K76908866-001-07-6 | ACH-001016 | BECKER_CENTRAL_NERVOUS_SYSTEM | MTS010 | 1 | 1.388364 | 0.75852 | 0.090671 | 1 | 43.236575 | null | CP-724714 | EGFR inhibitor, protein tyrosine kinase inhibitor | ERBB2 | null | null | COCC(=O)NC\C=C\c1ccc2ncnc(Nc3ccc(Oc4ccc(C)nc4)c(C)c3)c2c1 | Phase 2 | true | ACH-001016 |
BRD-K77625799-001-07-7 | ACH-001016 | BECKER_CENTRAL_NERVOUS_SYSTEM | MTS010 | 1 | 0.877266 | -0.964701 | 0.221789 | 0.94259 | 0.056782 | null | vandetanib | EGFR inhibitor, RET tyrosine kinase inhibitor, VEGFR inhibitor | EGFR, EPHA1, EPHA10, EPHA2, EPHA3, EPHA4, EPHA5, EPHA6, EPHA7, EPHA8, EPHB1, EPHB2, EPHB3, EPHB4, EPHB6, ERBB2, ERBB3, ERBB4, FLT1, FLT4, KDR, PTK6, RET, SRC, TEK, VEGFA | oncology | medullary thyroid cancer (MTC) | COc1cc2c(Nc3ccc(Br)cc3F)ncnc2cc1OCC1CCN(C)CC1 | Launched | true | ACH-001016 |
BRD-K78431006-001-15-1 | ACH-001016 | BECKER_CENTRAL_NERVOUS_SYSTEM | MTS010 | 1 | 0.866677 | -2.717052 | 0.009743 | 0.917044 | 0.255727 | null | crizotinib | ALK tyrosine kinase receptor inhibitor | ALK, MET | oncology | non-small cell lung cancer (NSCLC) | C[C@@H](Oc1cc(cnc1N)-c1cnn(c1)C1CCNCC1)c1c(Cl)ccc(F)c1Cl, C[C@@H](Oc1cc(cnc1N)-c1cnn(c1)C1CCNCC1)c1c(Cl)ccc(F)c1Cl, C[C@@H](Oc1cc(cnc1N)-c1cnn(c1)C1CCNCC1)c1c(Cl)ccc(F)c1Cl | Launched | true | ACH-001016 |
BRD-K79254416-001-21-8 | ACH-001016 | BECKER_CENTRAL_NERVOUS_SYSTEM | MTS010 | 1 | 0.813909 | -0.183088 | -0.004392 | 0.918158 | 0.019125 | null | decitabine | DNA methyltransferase inhibitor | DNMT1, DNMT3A | hematologic malignancy, hematology | myelodysplastic diseases (MDS), anemia, chronic myeloid leukemia (CML) | Nc1ncn([C@H]2C[C@H](O)[C@@H](CO)O2)c(=O)n1, Nc1ncn([C@H]2C[C@H](O)[C@@H](CO)O2)c(=O)n1, Nc1ncn([C@H]2C[C@H](O)[C@@H](CO)O2)c(=O)n1 | Launched | true | ACH-001016 |
BRD-K81016934-001-02-0 | ACH-001016 | BECKER_CENTRAL_NERVOUS_SYSTEM | MTS010 | 1 | 0.881137 | -6.207354 | 0.262184 | 0.942739 | 0.065422 | null | INC-280 | c-Met inhibitor | MET | null | null | CNC(=O)c1ccc(cc1F)-c1cnc2ncc(Cc3ccc4ncccc4c3)n2n1 | Phase 2 | true | ACH-001016 |
BRD-K81418486-001-44-2 | ACH-001016 | BECKER_CENTRAL_NERVOUS_SYSTEM | MTS010 | 1 | 1.071884 | 0.065982 | -0.031951 | 1 | 14.049084 | null | vorinostat | HDAC inhibitor | HDAC1, HDAC10, HDAC11, HDAC2, HDAC3, HDAC5, HDAC6, HDAC8, HDAC9 | hematologic malignancy | cutaneous T-cell lymphoma (CTCL) | ONC(=O)CCCCCCC(=O)Nc1ccccc1, ONC(=O)CCCCCCC(=O)Nc1ccccc1, ONC(=O)CCCCCCC(=O)Nc1ccccc1 | Launched | true | ACH-001016 |
BRD-K81473043-001-19-5 | ACH-001016 | BECKER_CENTRAL_NERVOUS_SYSTEM | MTS010 | 1 | 0.350907 | 9.113259 | 0.868694 | 0.867782 | 0.086558 | 0.098849 | tanespimycin | HSP inhibitor | HSP90AA1 | null | null | CO[C@H]1C[C@H](C)CC2=C(NCC=C)C(=O)C=C(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O, CO[C@H]1C[C@H](C)CC2=C(NCC=C)C(=O)C=C(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O | Phase 3 | true | ACH-001016 |
BRD-K82135108-001-04-3 | ACH-001016 | BECKER_CENTRAL_NERVOUS_SYSTEM | MTS010 | 1 | 0.604173 | 1.407147 | 0.433482 | 0.785213 | 0.051594 | null | elesclomol | oxidative stress inducer | HSPA1A | null | null | CN(NC(=O)CC(=O)NN(C)C(=S)c1ccccc1)C(=S)c1ccccc1 | Phase 3 | true | ACH-001016 |
BRD-K82746043-001-19-3 | ACH-001016 | BECKER_CENTRAL_NERVOUS_SYSTEM | MTS010 | 1 | 0.486049 | 1.272632 | 0.668661 | 0.673107 | 0.020683 | 0.344331 | navitoclax | BCL inhibitor | BCL2, BCL2L1, BCL2L2 | null | null | CC1(C)CCC(=C(CN2CCN(CC2)c2ccc(cc2)C(=O)NS(=O)(=O)c2ccc(N[C@H](CCN3CCOCC3)CSc3ccccc3)c(c2)S(=O)(=O)C(F)(F)F)C1)c1ccc(Cl)cc1, CC1(C)CCC(=C(CN2CCN(CC2)c2ccc(cc2)C(=O)NS(=O)(=O)c2ccc(N[C@H](CCN3CCOCC3)CSc3ccccc3)c(c2)S(=O)(=O)C(F)(F)F)C1)c1ccc(Cl)cc1 | Phase 2 | true | ACH-001016 |
BRD-K82818427-001-04-8 | ACH-001016 | BECKER_CENTRAL_NERVOUS_SYSTEM | MTS010 | 1 | 0.724077 | 0.015363 | 0.009452 | 0.861563 | 0.04987 | null | batimastat | matrix metalloprotease inhibitor | ADAM28, ADAMTS5, MMP12, MMP16, MMP2, MMP8 | null | null | CNC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(C)C)[C@H](CSc1cccs1)C(=O)NO, CNC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(C)C)[C@H](CSc1cccs1)C(=O)NO | Phase 3 | true | ACH-001016 |
BRD-K83029223-001-01-3 | ACH-001016 | BECKER_CENTRAL_NERVOUS_SYSTEM | MTS010 | 1 | 0.11813 | 13.828739 | 0.972164 | 0.485227 | 0.002165 | 0.002208 | litronesib | kinesin-like spindle protein inhibitor | KIF11 | null | null | CCNCCS(=O)(=O)NC[C@]1(SC(NC(=O)C(C)(C)C)=NN1C(=O)C(C)(C)C)c1ccccc1 | Phase 2 | true | ACH-001016 |
BRD-K83988098-001-02-0 | ACH-001016 | BECKER_CENTRAL_NERVOUS_SYSTEM | MTS010 | 1 | 0.340716 | 7.956096 | 0.902615 | 0.830341 | 0.01284 | 0.014826 | alvespimycin | HSP inhibitor | HSP90AA1 | null | null | CO[C@H]1C[C@H](C)CC2=C(NCCN(C)C)C(=O)C=C(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O, CO[C@H]1C[C@H](C)CC2=C(NCCN(C)C)C(=O)C=C(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O | Phase 2 | true | ACH-001016 |
BRD-K85402309-043-01-9 | ACH-001016 | BECKER_CENTRAL_NERVOUS_SYSTEM | MTS010 | 1 | 1.388069 | 1.285277 | 0.631965 | 1 | 0.605308 | null | dovitinib | EGFR inhibitor, FGFR inhibitor, FLT3 inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor | CSF1R, EGFR, FGFR1, FGFR2, FGFR3, FLT1, FLT3, FLT4, INSR, KDR, KIT, PDGFRA, PDGFRB | null | null | CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O, CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O, CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O, CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O, CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O, CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O | Phase 3 | true | ACH-001016 |
BRD-K85606544-001-09-1 | ACH-001016 | BECKER_CENTRAL_NERVOUS_SYSTEM | MTS010 | 1 | 0.793981 | -0.134927 | 0.068053 | 0.897217 | 0.075508 | null | neratinib | EGFR inhibitor | EGFR, ERBB2, KDR | null | null | CCOc1cc2ncc(C#N)c(Nc3ccc(OCc4ccccn4)c(Cl)c3)c2cc1NC(=O)\C=C\CN(C)C | Phase 3 | true | ACH-001016 |
BRD-K86118762-001-01-8 | ACH-001016 | BECKER_CENTRAL_NERVOUS_SYSTEM | MTS010 | 1 | 1.222017 | 1.05762 | 0.307552 | 1 | 0.262667 | null | linsitinib | IGF-1 inhibitor | IGF1R, INSR, INSRR | null | null | C[C@@]1(O)C[C@@H](C1)c1nc(-c2ccc3ccc(nc3c2)-c2ccccc2)c2c(N)nccn12, C[C@@]1(O)C[C@@H](C1)c1nc(-c2ccc3ccc(nc3c2)-c2ccccc2)c2c(N)nccn12 | Phase 3 | true | ACH-001016 |
BRD-K86972824-001-01-4 | ACH-001016 | BECKER_CENTRAL_NERVOUS_SYSTEM | MTS010 | 1 | 0.881516 | 0.442538 | 0.108761 | 0.949097 | 0.185989 | null | oltipraz | nuclear factor erythroid derived, like (NRF2) activator | ANG | null | null | Cc1c(ssc1=S)-c1cnccn1, Cc1c(ssc1=S)-c1cnccn1 | Phase 3 | true | ACH-001016 |
BRD-K87737963-001-06-0 | ACH-001016 | BECKER_CENTRAL_NERVOUS_SYSTEM | MTS010 | 1 | 0.843899 | 0.287819 | 0.058463 | 0.921203 | 0.072318 | null | cyt387 | null | JAK1, JAK2, JAK3 | null | null | O=C(NCC#N)c1ccc(cc1)-c1ccnc(Nc2ccc(cc2)N2CCOCC2)n1, O=C(NCC#N)c1ccc(cc1)-c1ccnc(Nc2ccc(cc2)N2CCOCC2)n1 | Phase 3 | true | ACH-001016 |
BRD-K87782578-001-01-4 | ACH-001016 | BECKER_CENTRAL_NERVOUS_SYSTEM | MTS010 | 1 | 1.108538 | 0.745032 | 0.097563 | 1 | 0.377589 | null | AVL-292 | Bruton's tyrosine kinase (BTK) inhibitor | BTK, YES1 | null | null | COCCOc1ccc(Nc2ncc(F)c(Nc3cccc(NC(=O)C=C)c3)n2)cc1 | Phase 2 | true | ACH-001016 |
BRD-K87909389-003-03-4 | ACH-001016 | BECKER_CENTRAL_NERVOUS_SYSTEM | MTS010 | 1 | 0.17509 | 1.523272 | 0.876537 | 0.643739 | 0.151423 | 0.200948 | alvocidib | CDK inhibitor | CDK1, CDK2, CDK4, CDK5, CDK6, CDK7, CDK8, CDK9, EGFR, PYGM | null | null | CN1CC[C@@H]([C@H](O)C1)c1c(O)cc(O)c2c1oc(cc2=O)-c1ccccc1Cl, CN1CC[C@@H]([C@H](O)C1)c1c(O)cc(O)c2c1oc(cc2=O)-c1ccccc1Cl | Phase 2 | true | ACH-001016 |
BRD-K88510285-001-17-8 | ACH-001016 | BECKER_CENTRAL_NERVOUS_SYSTEM | MTS010 | 1 | 0.152196 | 1.376417 | 0.880724 | 0.714145 | 0.095681 | 0.124553 | bortezomib | NFkB pathway inhibitor, proteasome inhibitor | PSMA1, PSMA2, PSMA3, PSMA4, PSMA5, PSMA6, PSMA7, PSMA8, PSMB1, PSMB10, PSMB11, PSMB2, PSMB3, PSMB4, PSMB5, PSMB6, PSMB7, PSMB8, PSMB9, PSMD1, PSMD2, RELA | hematologic malignancy | multiple myeloma, mantle cell lymphoma (MCL) | CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O, CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O, CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O, CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O, CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O | Launched | true | ACH-001016 |
BRD-K89014967-001-04-3 | ACH-001016 | BECKER_CENTRAL_NERVOUS_SYSTEM | MTS010 | 1 | 0.849092 | -0.144014 | -0.033002 | 0.941824 | 0.002697 | null | AS-703026 | MEK inhibitor | MAP2K1, MAP2K2 | null | null | OC[C@@H](O)CNC(=O)c1ccncc1Nc1ccc(I)cc1F | Phase 2 | true | ACH-001016 |
BRD-K92441787-001-04-1 | ACH-001016 | BECKER_CENTRAL_NERVOUS_SYSTEM | MTS010 | 1 | 0.918948 | -0.858534 | -0.090706 | 0.965391 | 0.037553 | null | bexarotene | retinoid receptor agonist | RXRA, RXRB, RXRG | hematologic malignancy | cutaneous T-cell lymphoma (CTCL) | Cc1cc2c(cc1C(=C)c1ccc(cc1)C(O)=O)C(C)(C)CCC2(C)C | Launched | true | ACH-001016 |
BRD-K95142244-001-01-5 | ACH-001016 | BECKER_CENTRAL_NERVOUS_SYSTEM | MTS010 | 1 | 0.77234 | 0.343187 | 0.13918 | 0.90471 | 0.250985 | null | talazoparib | PARP inhibitor | PARP2 | null | null | Cn1ncnc1[C@@H]1[C@H](Nc2cc(F)cc3c2c1n[nH]c3=O)c1ccc(F)cc1 | Phase 3 | true | ACH-001016 |
BRD-K96123349-236-02-8 | ACH-001016 | BECKER_CENTRAL_NERVOUS_SYSTEM | MTS010 | 1 | 1.034614 | -0.048879 | -0.002459 | 1 | 54,266,121.7286 | null | brequinar | dihydroorotate dehydrogenase inhibitor | DHODH | null | null | Cc1c(nc2ccc(F)cc2c1C(O)=O)-c1ccc(cc1)-c1ccccc1F | Phase 2 | true | ACH-001016 |
BRD-K98572433-001-02-9 | ACH-001016 | BECKER_CENTRAL_NERVOUS_SYSTEM | MTS010 | 1 | 0.845163 | 0.404338 | 0.114949 | 0.948413 | 0.713095 | null | AZD8931 | EGFR inhibitor | EGFR, ERBB2, ERBB3 | null | null | CNC(=O)CN1CCC(CC1)Oc1cc2c(Nc3cccc(Cl)c3F)ncnc2cc1OC | Phase 2 | true | ACH-001016 |
BRD-K99113996-001-02-0 | ACH-001016 | BECKER_CENTRAL_NERVOUS_SYSTEM | MTS010 | 1 | 0.785444 | 0.93659 | 0.061987 | 0.934122 | 0.21432 | null | AZD2014 | mTOR inhibitor | MTOR | null | null | CNC(=O)c1cccc(c1)-c1ccc2c(nc(nc2n1)N1CCOC[C@@H]1C)N1CCOC[C@@H]1C | Phase 2 | true | ACH-001016 |
BRD-K99616396-001-05-1 | ACH-001016 | BECKER_CENTRAL_NERVOUS_SYSTEM | MTS010 | 1 | 1.055795 | 0.087572 | -0.019223 | 1 | 14.398293 | null | motesanib | KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor | FLT1, FLT4, KDR, KIT | null | null | CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc12, CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc12, CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc12, CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc12, CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc12 | Phase 3 | true | ACH-001016 |
BRD-K99749624-001-07-0 | ACH-001016 | BECKER_CENTRAL_NERVOUS_SYSTEM | MTS010 | 1 | 1.097746 | 0.319957 | 0.011187 | 1 | 0.020197 | null | linifanib | PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor | CSF1, CSF1R, FLT1, FLT3, FLT4, KDR, KIT, PDGFRB, RET, TEK | null | null | Cc1ccc(F)c(NC(=O)Nc2ccc(cc2)-c2cccc3[nH]nc(N)c23)c1 | Phase 3 | true | ACH-001016 |
BRD-M97302542-001-04-4 | ACH-001016 | BECKER_CENTRAL_NERVOUS_SYSTEM | MTS010 | 1 | 1.143717 | -0.254914 | 0.06957 | 1 | 0.088606 | null | dichloroacetate | pyruvate dehydrogenase kinase inhibitor | PDK1 | null | null | [Na].OC(=O)C(Cl)Cl, [Na].OC(=O)C(Cl)Cl | Phase 3 | true | ACH-001016 |
BRD-A25234499-001-19-1 | ACH-001024 | CHL1_SKIN | MTS010 | 1 | 0.962723 | 0.104614 | -0.016996 | 0.975721 | 0.000176 | null | aminoglutethimide | glucocorticoid receptor antagonist | CYP11A1, CYP19A1 | endocrinology, oncology | Cushing's syndrome, breast cancer | CCC1(CCC(=O)NC1=O)c1ccc(N)cc1, CCC1(CCC(=O)NC1=O)c1ccc(N)cc1, CCC1(CCC(=O)NC1=O)c1ccc(N)cc1 | Launched | true | ACH-001024 |
BRD-A70858459-001-01-7 | ACH-001024 | CHL1_SKIN | MTS010 | 1 | 0.72032 | -3.501909 | 0.063619 | 0.95751 | 0.00266 | null | estramustine | DNA alkylating agent | ESR1, ESR2, MAP1A, MAP2 | oncology | prostate cancer | C[C@]12CCC3C(CCc4cc(OC(=O)N(CCCl)CCCl)ccc34)C1CC[C@@H]2O | Launched | true | ACH-001024 |
BRD-A74914197-001-02-9 | ACH-001024 | CHL1_SKIN | MTS010 | 1 | 0.642182 | 4.165081 | 0.601255 | 0.835769 | 0.007266 | null | pralatrexate | dihydrofolate reductase inhibitor | DHFR, TYMS | hematologic malignancy | peripheral T-cell lymphoma (PTCL) | Nc1nc(N)c2nc(CC(CC#C)c3ccc(cc3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)cnc2n1 | Launched | true | ACH-001024 |
BRD-K02113016-001-19-6 | ACH-001024 | CHL1_SKIN | MTS010 | 1 | 0.784795 | 0.779628 | 0.050799 | 0.931104 | 0.500261 | null | olaparib | PARP inhibitor | PARP1, PARP2 | oncology | ovarian cancer | Fc1ccc(Cc2n[nH]c(=O)c3ccccc23)cc1C(=O)N1CCN(CC1)C(=O)C1CC1, Fc1ccc(Cc2n[nH]c(=O)c3ccccc23)cc1C(=O)N1CCN(CC1)C(=O)C1CC1 | Launched | true | ACH-001024 |
BRD-K02130563-001-11-4 | ACH-001024 | CHL1_SKIN | MTS010 | 1 | 0.015214 | 0.53673 | 0.743328 | 0.587331 | 0.195171 | 0.206738 | panobinostat | HDAC inhibitor | HDAC1, HDAC2, HDAC3, HDAC4, HDAC6, HDAC7, HDAC8, HDAC9 | hematologic malignancy | multiple myeloma | Cc1[nH]c2ccccc2c1CCNCc1ccc(\C=C\C(=O)NO)cc1, Cc1[nH]c2ccccc2c1CCNCc1ccc(\C=C\C(=O)NO)cc1, Cc1[nH]c2ccccc2c1CCNCc1ccc(\C=C\C(=O)NO)cc1, Cc1[nH]c2ccccc2c1CCNCc1ccc(\C=C\C(=O)NO)cc1 | Launched | true | ACH-001024 |
BRD-K03390685-001-01-7 | ACH-001024 | CHL1_SKIN | MTS010 | 1 | 2.072611 | 0.746231 | 0.670342 | 1 | 1.445606 | null | cobimetinib | MEK inhibitor | null | oncology | melanoma | OC1(CN(C1)C(=O)c1ccc(F)c(F)c1Nc1ccc(I)cc1F)[C@@H]1CCCCN1 | Launched | true | ACH-001024 |
BRD-K03406345-001-21-1 | ACH-001024 | CHL1_SKIN | MTS010 | 1 | 0.878866 | 0.317174 | 0.057269 | 0.93202 | 0.031054 | null | azacitidine | DNA methyltransferase inhibitor | DNMT1, DNMT3A | hematologic malignancy, hematology | myelodysplastic diseases (MDS), anemia, chronic myelomonocytic leukemia (CMMoL) | Nc1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-001024 |
BRD-K03449891-001-08-6 | ACH-001024 | CHL1_SKIN | MTS010 | 1 | 0.066375 | 9.514358 | 0.800573 | 0.854858 | 2.212001 | 2.245367 | foretinib | VEGFR inhibitor | FLT1, FLT4, KDR, MET | null | null | COc1cc2c(Oc3ccc(NC(=O)C4(CC4)C(=O)Nc4ccc(F)cc4)cc3F)ccnc2cc1OCCCN1CCOCC1 | Phase 2 | true | ACH-001024 |
BRD-K03765900-001-01-9 | ACH-001024 | CHL1_SKIN | MTS010 | 1 | 0.575735 | 0.540161 | 0.156622 | 0.78168 | 0.066305 | null | XL-647 | EGFR inhibitor, VEGFR inhibitor | EGFR, EPHB4, ERBB2, FLT4, KDR | null | null | COc1cc2c(Nc3ccc(Cl)c(Cl)c3F)ncnc2cc1OC[C@H]1C[C@H]2CN(C)C[C@H]2C1 | Phase 3 | true | ACH-001024 |
BRD-K06814349-304-02-7 | ACH-001024 | CHL1_SKIN | MTS010 | 1 | 0.248373 | 0.846287 | 0.63945 | 0.81285 | 1.048584 | 2.360376 | fosbretabulin | tubulin polymerization inhibitor, VE-cadherin antagonist | CDH5 | null | null | COc1ccc(C=Cc2cc(OC)c(OC)c(OC)c2)cc1OP(O)(O)=O, COc1ccc(cc1OP(O)(O)=O)\C=C/c1cc(OC)c(OC)c(OC)c1, COc1ccc(cc1OP(O)(O)=O)\C=C/c1cc(OC)c(OC)c(OC)c1, COc1ccc(C=Cc2cc(OC)c(OC)c(OC)c2)cc1OP(O)(O)=O | Phase 3 | true | ACH-001024 |
BRD-K08109215-001-06-4 | ACH-001024 | CHL1_SKIN | MTS010 | 1 | 0.756441 | 1.299616 | 0.247639 | 0.903772 | 0.217247 | null | I-BET-762 | bromodomain inhibitor | BRD2, BRD3, BRD4 | null | null | CCNC(=O)C[C@@H]1N=C(c2ccc(Cl)cc2)c2cc(OC)ccc2-n2c(C)nnc12 | Phase 2 | true | ACH-001024 |
BRD-K08542803-001-02-3 | ACH-001024 | CHL1_SKIN | MTS010 | 1 | 0.063271 | 3.292409 | 0.927987 | 0.659649 | 0.2942 | 0.306546 | gambogic-acid | caspase activator | BCL2 | null | null | CC(C)=CCC[C@@]1(C)Oc2c(CC=C(C)C)c3O[C@@]45[C@H]6C[C@@H](C=C4C(=O)c3c(O)c2C=C1)C(=O)[C@]5(C\C=C(\C)C(O)=O)OC6(C)C, CC(C)=CCC[C@@]1(C)Oc2c(CC=C(C)C)c3O[C@@]45[C@H]6C[C@@H](C=C4C(=O)c3c(O)c2C=C1)C(=O)[C@]5(C\C=C(\C)C(O)=O)OC6(C)C, CC(C)=CCC[C@@]1(C)Oc2c(CC=C(C)C)c3O[C@@]45[C@H]6C[C@@H](C=C4C(=O)c3c(O)c2C=C1)C(=O)[C@]5(C\C=C(\C)C(O)=O)OC6(C)C | Phase 2 | true | ACH-001024 |
BRD-K08547377-001-04-4 | ACH-001024 | CHL1_SKIN | MTS010 | 1 | -0.103401 | 2.590317 | 0.524634 | 0.941341 | 6.715202 | 6.245157 | irinotecan | topoisomerase inhibitor | TOP1, TOP1MT | oncology | colorectal cancer | CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12 | Launched | true | ACH-001024 |
BRD-K08703257-001-13-9 | ACH-001024 | CHL1_SKIN | MTS010 | 1 | 1.260889 | 0.33024 | 0.156242 | 1 | 0.858767 | null | 3-amino-benzamide | PARP inhibitor | PARP1 | null | null | NC(=O)c1cccc(N)c1, NC(=O)c1cccc(N)c1 | Phase 2 | true | ACH-001024 |
BRD-K08799216-001-05-3 | ACH-001024 | CHL1_SKIN | MTS010 | 1 | 0.582188 | 10.752549 | 0.567928 | 0.851772 | 0.319707 | null | pelitinib | EGFR inhibitor | EGFR | null | null | CCOc1cc2ncc(C#N)c(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)\C=C\CN(C)C | Phase 2 | true | ACH-001024 |
BRD-K09951645-001-11-8 | ACH-001024 | CHL1_SKIN | MTS010 | 1 | 0.882161 | -0.031159 | -0.069577 | 0.915051 | 1,386,019,141,856.085 | null | dabrafenib | RAF inhibitor | BRAF, LIMK1, NEK11, RAF1, SIK1 | oncology | melanoma | CC(C)(C)c1nc(c(s1)-c1ccnc(N)n1)-c1cccc(NS(=O)(=O)c2c(F)cccc2F)c1F, CC(C)(C)c1nc(c(s1)-c1ccnc(N)n1)-c1cccc(NS(=O)(=O)c2c(F)cccc2F)c1F, CC(C)(C)c1nc(c(s1)-c1ccnc(N)n1)-c1cccc(NS(=O)(=O)c2c(F)cccc2F)c1F | Launched | true | ACH-001024 |
BRD-K11267252-001-05-1 | ACH-001024 | CHL1_SKIN | MTS010 | 1 | 0.883367 | 2.950291 | -0.202338 | 0.930384 | 0.030502 | null | alectinib | ALK tyrosine kinase receptor inhibitor | ALK, MET | oncology | non-small cell lung cancer (NSCLC) | CCc1cc2C(=O)c3c([nH]c4cc(ccc34)C#N)C(C)(C)c2cc1N1CCC(CC1)N1CCOCC1, CCc1cc2C(=O)c3c([nH]c4cc(ccc34)C#N)C(C)(C)c2cc1N1CCC(CC1)N1CCOCC1 | Launched | true | ACH-001024 |
BRD-K11630072-001-13-2 | ACH-001024 | CHL1_SKIN | MTS010 | 1 | 0.83508 | 0.121197 | 0.048884 | 0.913296 | 0.032573 | null | carmofur | thymidylate synthase inhibitor | TYMS | oncology | breast cancer, colorectal cancer | CCCCCCNC(=O)n1cc(F)c(=O)[nH]c1=O, CCCCCCNC(=O)n1cc(F)c(=O)[nH]c1=O, CCCCCCNC(=O)n1cc(F)c(=O)[nH]c1=O | Launched | true | ACH-001024 |
BRD-K12184916-001-19-6 | ACH-001024 | CHL1_SKIN | MTS010 | 1 | 0.260832 | 2.308313 | 0.488862 | 0.506425 | 0.014926 | 0.020545 | NVP-BEZ235 | mTOR inhibitor, PI3K inhibitor | ATR, MTOR, PIK3CA, PIK3CD, PIK3CG | null | null | Cn1c2cnc3ccc(cc3c2n(-c2ccc(cc2)C(C)(C)C#N)c1=O)-c1cnc2ccccc2c1, Cn1c2cnc3ccc(cc3c2n(-c2ccc(cc2)C(C)(C)C#N)c1=O)-c1cnc2ccccc2c1 | Phase 2 | true | ACH-001024 |
BRD-K13049116-001-04-0 | ACH-001024 | CHL1_SKIN | MTS010 | 1 | 1.00795 | -0.006832 | -0.00003 | 1 | 156,475,146,563,467,310,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000 | null | BMS-754807 | IGF-1 inhibitor | AKT1, IGF1R | null | null | C[C@]1(CCCN1c1nc(Nc2cc(n[nH]2)C2CC2)c2cccn2n1)C(=O)Nc1ccc(F)nc1, C[C@]1(CCCN1c1nc(Nc2cc(n[nH]2)C2CC2)c2cccn2n1)C(=O)Nc1ccc(F)nc1, C[C@]1(CCCN1c1nc(Nc2cc(n[nH]2)C2CC2)c2cccn2n1)C(=O)Nc1ccc(F)nc1 | Phase 2 | true | ACH-001024 |
BRD-K13390322-001-06-3 | ACH-001024 | CHL1_SKIN | MTS010 | 1 | 0.100831 | 7.476373 | 0.823708 | 0.766499 | 0.804476 | 0.829067 | AT-7519 | CDK inhibitor | CDK1, CDK2, CDK4, CDK5, CDK6, CDK9 | null | null | Clc1cccc(Cl)c1C(=O)Nc1c[nH]nc1C(=O)NC1CCNCC1 | Phase 2 | true | ACH-001024 |
BRD-K13514097-001-04-6 | ACH-001024 | CHL1_SKIN | MTS010 | 1 | 0.802907 | 0.095543 | 0.008627 | 0.890721 | 0.007602 | null | everolimus | mTOR inhibitor | MTOR | oncology, neurology/psychiatry, genetics, urology | breast cancer, neuroendocrine tumors of pancreatic origin (PNET), renal cell carcinoma (RCC), subependymal giant cell astrocytoma (SEGA), tuberous sclerosis complex (TSC), renal angiomyolipoma | CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@H]1OCCO, CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@H]1OCCO | Launched | true | ACH-001024 |
BRD-K13662825-001-07-5 | ACH-001024 | CHL1_SKIN | MTS010 | 1 | 0.066509 | 1.606587 | 0.792041 | 0.517384 | 0.016582 | 0.018122 | dinaciclib | CDK inhibitor | CDK1, CDK2, CDK5, CDK9 | null | null | CCc1cnn2c(NCc3ccc[n+]([O-])c3)cc(nc12)N1CCCC[C@H]1CCO | Phase 3 | true | ACH-001024 |
BRD-K15179879-001-03-2 | ACH-001024 | CHL1_SKIN | MTS010 | 1 | 0.103868 | 1.14816 | 0.913913 | 0.433669 | 0.021402 | 0.026214 | carfilzomib | proteasome inhibitor | PSMA1, PSMA2, PSMA3, PSMA4, PSMA5, PSMA6, PSMA7, PSMA8, PSMB1, PSMB10, PSMB11, PSMB2, PSMB3, PSMB4, PSMB5, PSMB6, PSMB7, PSMB8, PSMB9 | hematologic malignancy | multiple myeloma | CC(C)C[C@H](NC(=O)[C@H](CCc1ccccc1)NC(=O)CN1CCOCC1)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CC(C)C)C(=O)[C@@]1(C)CO1 | Launched | true | ACH-001024 |
BRD-K15600710-066-05-8 | ACH-001024 | CHL1_SKIN | MTS010 | 1 | -0.317099 | 0.741616 | 0.630919 | 0.787525 | 3.393989 | 1.750206 | obatoclax | BCL inhibitor | BCL2 | null | null | COC1=CC(=N\C\1=C/c1[nH]c(C)cc1C)c1cc2ccccc2[nH]1, COC1=CC(=N\C\1=C/c1[nH]c(C)cc1C)c1cc2ccccc2[nH]1 | Phase 3 | true | ACH-001024 |
BRD-K17555800-003-02-3 | ACH-001024 | CHL1_SKIN | MTS010 | 1 | 0.800169 | 1.253904 | 0.06251 | 0.987942 | 9.376773 | null | talmapimod | p38 MAPK inhibitor | MAPK11, MAPK14 | null | null | C[C@H]1CN([C@H](C)CN1Cc1ccc(F)cc1)C(=O)c1cc2c(cn(C)c2cc1Cl)C(=O)C(=O)N(C)C, C[C@H]1CN([C@H](C)CN1Cc1ccc(F)cc1)C(=O)c1cc2c(cn(C)c2cc1Cl)C(=O)C(=O)N(C)C, C[C@H]1CN([C@H](C)CN1Cc1ccc(F)cc1)C(=O)c1cc2c(cn(C)c2cc1Cl)C(=O)C(=O)N(C)C | Phase 2 | true | ACH-001024 |
BRD-K17610631-001-03-3 | ACH-001024 | CHL1_SKIN | MTS010 | 1 | 1.003554 | -0.613024 | -0.024811 | 1 | 0.371252 | null | indisulam | CDK inhibitor | CA1, CA12, CA14, CA2, CA6, CA7, CA9 | null | null | NS(=O)(=O)c1ccc(cc1)S(=O)(=O)Nc1cccc2c(Cl)c[nH]c12 | Phase 2 | true | ACH-001024 |
BRD-K17743125-001-08-4 | ACH-001024 | CHL1_SKIN | MTS010 | 1 | 0.292493 | 4.444108 | 0.731858 | 0.891434 | 2.256292 | 2.750008 | belinostat | HDAC inhibitor | HDAC1, HDAC10, HDAC11, HDAC2, HDAC3, HDAC4, HDAC5, HDAC6, HDAC7, HDAC8, HDAC9 | hematologic malignancy | peripheral T-cell lymphoma (PTCL) | ONC(=O)\C=C\c1cccc(c1)S(=O)(=O)Nc1ccccc1 | Launched | true | ACH-001024 |
BRD-K17894950-001-14-3 | ACH-001024 | CHL1_SKIN | MTS010 | 1 | 1.202353 | -0.559642 | 0.053179 | 1 | 0.002344 | null | indirubin | CDK inhibitor, glycogen synthase kinase inhibitor | CDK1, CDK5, GSK3A | null | null | O=C1Nc2ccccc2\C1=C1\Nc2ccccc2C1=O | Phase 2/Phase 3 | true | ACH-001024 |
BRD-K18961567-001-01-1 | ACH-001024 | CHL1_SKIN | MTS010 | 1 | 0.625868 | 7.17677 | 0.472645 | 0.923418 | 1.371789 | null | LY2801653 | MET inhibitor | MET | null | null | Cc1ccc(C(=O)Nc2ccc(Oc3cc4cnn(C)c4cc3-c3cn[nH]c3)c(F)c2)c(=O)n1-c1ccc(F)cc1 | Phase 2 | true | ACH-001024 |
BRD-K19540840-001-09-4 | ACH-001024 | CHL1_SKIN | MTS010 | 1 | 0.546045 | 0.326751 | 0.178542 | 0.819442 | 0.357518 | null | saracatinib | src inhibitor | ABL1, LCK, SRC, YES1 | null | null | CN1CCN(CCOc2cc(OC3CCOCC3)c3c(Nc4c5OCOc5ccc4Cl)ncnc3c2)CC1 | Phase 2/Phase 3 | true | ACH-001024 |
BRD-K19687926-001-04-1 | ACH-001024 | CHL1_SKIN | MTS010 | 1 | 0.859886 | 0.486407 | 0.066936 | 0.913873 | 0.02003 | null | lapatinib | EGFR inhibitor | EGFR, ERBB2 | oncology | breast cancer | CS(=O)(=O)CCNCc1ccc(o1)-c1ccc2ncnc(Nc3ccc(OCc4cccc(F)c4)c(Cl)c3)c2c1, CS(=O)(=O)CCNCc1ccc(o1)-c1ccc2ncnc(Nc3ccc(OCc4cccc(F)c4)c(Cl)c3)c2c1, CS(=O)(=O)CCNCc1ccc(o1)-c1ccc2ncnc(Nc3ccc(OCc4cccc(F)c4)c(Cl)c3)c2c1 | Launched | true | ACH-001024 |
BRD-K22064724-001-01-8 | ACH-001024 | CHL1_SKIN | MTS010 | 1 | -0.005777 | 0.676063 | 0.697013 | 0.548476 | 0.133378 | 0.131131 | napabucasin | STAT inhibitor | STAT3 | null | null | CC(=O)c1cc2c(o1)C(=O)c1ccccc1C2=O, CC(=O)c1cc2c(o1)C(=O)c1ccccc1C2=O | Phase 3 | true | ACH-001024 |
BRD-K22822991-001-02-3 | ACH-001024 | CHL1_SKIN | MTS010 | 1 | 1.388126 | -0.540448 | 0.326824 | 1 | 0.002912 | null | odanacatib | cathepsin inhibitor | CTSK | null | null | CC(C)(F)C[C@H](N[C@@H](c1ccc(cc1)-c1ccc(cc1)S(C)(=O)=O)C(F)(F)F)C(=O)NC1(CC1)C#N | Phase 3 | true | ACH-001024 |
BRD-K23228615-001-02-8 | ACH-001024 | CHL1_SKIN | MTS010 | 1 | 0.162664 | 7.623178 | 0.82934 | 0.864868 | 2.08845 | 2.199074 | GDC-0980 | mTOR inhibitor, PI3K inhibitor | FGR, MAP3K9, MTOR, PIK3CA, PIK3CB, PIK3CD, PIK3CG, SYK | null | null | C[C@H](O)C(=O)N1CCN(Cc2sc3c(nc(nc3c2C)-c2cnc(N)nc2)N2CCOCC2)CC1, C[C@H](O)C(=O)N1CCN(Cc2sc3c(nc(nc3c2C)-c2cnc(N)nc2)N2CCOCC2)CC1 | Phase 2 | true | ACH-001024 |
BRD-K26026438-001-01-0 | ACH-001024 | CHL1_SKIN | MTS010 | 1 | 0.611582 | 0.979331 | 0.514239 | 0.783753 | 0.044582 | null | tucatinib | EGFR inhibitor | ERBB2 | null | null | Cc1cc(Nc2ncnc3ccc(NC4=NC(C)(C)CO4)cc23)ccc1Oc1ccn2ncnc2c1 | Phase 2 | true | ACH-001024 |
BRD-K26657438-001-15-2 | ACH-001024 | CHL1_SKIN | MTS010 | 1 | 0.922925 | -0.22203 | -0.009418 | 0.947324 | 3.419568 | null | imiquimod | interferon inducer, toll-like receptor agonist | TLR7, TLR8 | dermatology, infectious disease, oncology | actinic keratosis (AK), genital warts, basal cell carcinoma (BCC) | CC(C)Cn1cnc2c(N)nc3ccccc3c12, CC(C)Cn1cnc2c(N)nc3ccccc3c12, CC(C)Cn1cnc2c(N)nc3ccccc3c12 | Launched | true | ACH-001024 |
BRD-K28822270-001-03-7 | ACH-001024 | CHL1_SKIN | MTS010 | 1 | 0.182548 | 6.809595 | 0.709538 | 0.885194 | 2.677923 | 2.862676 | resminostat | HDAC inhibitor | HDAC1, HDAC3, HDAC6, HDAC8 | null | null | CN(C)Cc1ccc(cc1)S(=O)(=O)n1ccc(c1)\C=C\C(=O)NO, CN(C)Cc1ccc(cc1)S(=O)(=O)n1ccc(c1)\C=C\C(=O)NO | Phase 2 | true | ACH-001024 |
BRD-K29905972-001-06-3 | ACH-001024 | CHL1_SKIN | MTS010 | 1 | 0.879784 | 3.56486 | 0.178009 | 0.957555 | 0.32503 | null | axitinib | PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor | CSF1, FLT1, FLT4, KDR, PLK4 | oncology | renal cell carcinoma (RCC) | CNC(=O)c1ccccc1Sc1ccc2c(\C=C\c3ccccn3)n[nH]c2c1, CNC(=O)c1ccccc1Sc1ccc2c(\C=C\c3ccccn3)n[nH]c2c1, CNC(=O)c1ccccc1Sc1ccc2c(\C=C\c3ccccn3)n[nH]c2c1, CNC(=O)c1ccccc1Sc1ccc2c(\C=C\c3ccccn3)n[nH]c2c1, CNC(=O)c1ccccc1Sc1ccc2c(\C=C\c3ccccn3)n[nH]c2c1 | Launched | true | ACH-001024 |
Subsets and Splits
No saved queries yet
Save your SQL queries to embed, download, and access them later. Queries will appear here once saved.